Adaptive chemo strategy aims to get more pancreatic cancer patients to surgery

NCT ID NCT04594772

Ongoing Disease control Sponsor: University of Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase II trial tests an adaptive chemotherapy approach for people with pancreatic cancer that can be removed by surgery. The goal is to see if adjusting the chemo regimen based on early response can increase the number of patients who become eligible for surgery. About 32 participants will receive either FOLFIRINOX or a gemcitabine-based combination, with the option to switch if needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (FOLFIRINOX and gemcitabine/nab-paclitaxel)
What this could lead to: If successful, this approach could help more pancreatic cancer patients become eligible for surgery, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply to all patients. Chemotherapy side effects can be severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREAS CANCER

Contacts and locations

Locations

University of Arizona

Tucson, Arizona, 85724, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.